Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. reports on the results of the annual meeting of shareholders held on March 31, 2021, for the fiscal year ending March 31, 2021. The filing was submitted on April 8, 2021.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
The primary material event reported is the successful conclusion of the annual shareholder meeting. Key voting outcomes include:
- Quorum: 5,195,424 shares were present, representing approximately 33.49% of the 15,514,398 outstanding ordinary shares.
- Election of Directors: All five nominees (Feng Zhou, Jun Zheng, Junsong Li, Xiaodong Ji, and Wenwei Fan) were elected unanimously with 5,195,424 votes "For" and 0 "Withheld."
- Accounting Firm Ratification: Shareholders ratified ZH CPA, LLC as the independent registered public accounting firm for the fiscal year ending March 31, 2021, with 5,195,424 votes "For" and 0 "Against" or "Abstain."
- Equity Incentive Plan: The 2021 Equity Incentive Plan was approved and declared effective immediately, with 5,195,424 votes "For" and 0 "Against" or "Abstain."
Guidance, Outlook, and Risks
The filing includes a standard "Special Note Regarding Forward-Looking Statements." It warns that statements regarding future events, trends, and expectations are subject to risks and uncertainties. The company explicitly states it undertakes no duty to update these statements after the date of the report. No specific operational guidance or new risk factors were detailed in this specific filing.
Investor Verification Checklist
- Verify the effective date and terms of the newly approved 2021 Equity Incentive Plan in subsequent filings.
- Review the full annual report (Form 20-F) for the fiscal year ended March 31, 2021, to obtain financial performance data not included in this 6-K.
- Confirm the tenure of the newly elected directors, which extends until the 2022 annual meeting.